Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 39Observational 2Expanded_access 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Neoplasms by Site 1Neoplasms 1HER2-positive Breast Cancer 1Breast Neoplasms 1Breast Diseases 1Brain Neoplasms 1

Interventions

veliparib 2tucatinib 2leronlimab 2abemaciclib 2Trastuzumab 2Capecitabine 2Alpelisib 2zenocutuzumab 1selpercatinib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1pegilodecakin 1palbociclib 1margetuximab 1iniparib 1glembatumumab vedotin 1gedatolisib 1eribulin 1Vinorelbine 1Proton Pump Inhibitors 1Letrozole 1Lapatinib 1Hydrocortisone 1Everolimus 1Cisplatin 1Ado-Trastuzumab Emtansine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × tucatinib × Breast × Clear all
NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Seagen Inc.

Approved for marketing
Breast

HER2-positive Breast Cancer

NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡